| Species |
Cynomolgus |
| Protein Construction |
GPA (Ser20-Glu91)
Accession # A0A2K5WD82 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
9 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 30-45 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Granulomatosis with polyangiitis (GPA) presents a wide spectrum of manifestations from the common respiratory symptoms to infrequent neurological and cardiac complications. The challenge in diagnosis and management makes the rapidly progressive disorder one of the most challenging dilemmas in clinical medicine.The ultimate goal is an improved prognosis through outcome measures which assesses the disease control with minimal adverse effects of intensive immunosuppressive regimens, an integral part of the clinical approach to improve the quality of life of GPA patients. |
| Synonyms |
Glycophorin-A; Glycophorin A; PAS-2; CD235a; GPA; GPErik; GpMiIII; GPSAT; GYPA; HGpMiIII; HGpMiV; HGpMiX; HGpMiXI; HGpSta(C); MNS; CD235a; MN |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
